Recent research have centered on the convergence of glucagon-like peptide-1|GIP|GCGR activator therapies and dopaminergic communication. While GCGR agonists are increasingly employed for addressing type 2 T2DM, their emerging consequences on motivation circuits, specifically mediated by DA pathways, are receiving substantial focus. This report pres